Phase Ib Clinical Trial to Evaluate the Safety Profile of the Combination Tilray FS Oral Solution T10:C10 with Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma.

2024-515546-16-00 Protocol GEINO -1601 Human pharmacology (Phase I) - Other Ended

Start 27 Aug 2024 · End 12 Nov 2025 · Status Ended · 1 EU/EEA countries · 8 sites · Protocol GEINO -1601

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 33
Countries 1
Sites 8

Glioblastoma

Key facts

Sponsor
Grupo Espanol De Investigacion En Neurooncologia
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
27 Aug 2024 → 12 Nov 2025
Decision date (initial)
2024-08-27
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-515546-16-00
EudraCT number
2016-003216-12
ClinicalTrials.gov
NCT03529448

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Glioblastoma

VersionLevelCodeTermSystem organ class
20.0 PT 10018336 Glioblastoma 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Grupo Espanol De Investigacion En Neurooncologia

Sponsor organisation
Grupo Espanol De Investigacion En Neurooncologia
Address
Calle De Velazquez 7 3a Planta
City
Madrid
Postcode
28001
Country
Spain

Scientific contact point

Organisation
Grupo Espanol De Investigacion En Neurooncologia
Contact name
A person designed by the Sponsor

Public contact point

Organisation
Grupo Espanol De Investigacion En Neurooncologia
Contact name
A person designed by the Sponsor

Locations

1 EU/EEA country · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 33 8
Rest of world 0

Investigational sites

Spain

8 sites · Ended
Hospital Universitario Regional De Malaga
Oncología Médica, Avenida De Carlos De Haya S/N, 29010, Malaga
Ajuntament De L Hospitalet De Llobregat
Oncología Médica, Calle D'amadeu Torner 63, 08902, L'hospitalet De Llobregat
Hospital Universitario 12 De Octubre
Oncología Médica, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Universitario De Salamanca
Oncología Médica, Paseo De San Vicente 58-182, 37007, Salamanca
Hospital Universitario Virgen De Las Nieves
Oncología Médica, Avenida De Las Fuerzas Armadas 2, 18014, Granada
University Hospital Virgen Del Rocio S.L.
Oncología Médica, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital Del Mar
Oncología Médica, Passeig Maritim De La Barceloneta 25-29, 08003, Barcelona
University Hospital Son Espases
Oncología Médica, Carretera Valldemossa 79, 07120, Palma

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2024-08-27 2025-11-12 2024-08-27 2024-08-27

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-14 Spain Acceptable with conditions
2024-08-27
2024-08-27